Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Contact

Portfolio News

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases

Portfolio News / By Karina Tin

September 17, 2020

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

Portfolio News / By Karina Tin

September 16, 2020

Hexagon Bio: This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi

Portfolio News / By Karina Tin

September 15, 2020

Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies

Portfolio News / By Karina Tin

September 15, 2020

Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus

Portfolio News / By Karina Tin

September 14, 2020

Casma Therapeutics Announces $50 Million Series B Financing

Portfolio News / By Karina Tin

September 10, 2020

NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

Portfolio News / By Karina Tin

August 29, 2020

RAPT Therapeutics Reports Second Quarter 2020 Financial Results

Portfolio News / By Karina Tin

August 13, 2020

NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results

Portfolio News / By Karina Tin

August 12, 2020

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Portfolio News / By Karina Tin

August 10, 2020

Posts navigation

1 2 … 17 Next Page →

Search for:

Recent Posts

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
Hexagon Bio: This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies
Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2020. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top